With the introduction of PARP inhibitors into clinical trials for the treatment of paediatric cancers, including HR-NB, a disease with one of the worst long term prognoses, and ATR inhibitors being tested in adult trials, we sought to investigate which NB specific DDR defects, if any, would lead to sensitivity to these agents alone and in combination. The gene discussed is ATR; the disease is neuroblastoma.